Elixir Medical Corporation

Print Article

PRESS RELEASE

Elixir Medical Corporation Expands Commercial Operations with Addition of Michele Perrino as President, Commercial and Manufacturing Operations

Sunnyvale, CASeptember 18, 2015—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that medical device executive Michele Perrino will join its management team as President, Commercial and Manufacturing Operations, on October 1, 2015. In this role, he will guide Elixir’s continuing buildup of its commercial and manufacturing operations including both direct sales forces and distributor operations, as the company expands rollout of its market-leading drug-eluting bioresorbable vascular scaffold, DESolve, and the launch of next-generation products.

Mr. Perrino has extensive experience building successful commercial operations internationally. He previously served in a number of senior management roles at Volcano Corporation, most recently as President International Operations.  Prior to that, he held various management positions for Ethicon Endo Surgery and Cordis, divisions of Johnson & Johnson, Inc. Mr. Perrino received a Master’s degree in Economics and a post-graduate Degree in Finance from the University of Bari (Italy).

 

“We are extremely pleased to have Michele on the Elixir team as we continue to expand the commercial and manufacturing operations around our industry-leading drug-eluting bioresorbable scaffold and drug-eluting stent platforms,” said Motasim Sirhan, CEO and Founder of Elixir Medical.   

 

Elixir also announced that Chief Commercial Officer Stefan Richter will move into a strategic advisory role reporting to CEO Motasim Sirhan to accommodate Mr. Richter’s family needs.  “We thank Stefan for all his valuable contributions in building the commercial operation at Elixir and look forward to working with him in his new role.” said Mr. Sirhan.

 

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com

***

Contact:

Donna Collins 

Phone: (408) 636-2060